CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib

The targeted treatment of advanced non-small cell lung cancer (NSCLC) harboring genomic rearrangement of ALK is a paradigm for personalized oncology. More than 15 different ALK fusion partners have been discovered in NSCLC patients. Most of these ALK fusions responded well to the ALK inhibitor crizo...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Xue, Shao, Yun, Gao, Hongjun, Zhang, Xueli, Zhang, Han, Ban, Yi, Qin, Haifeng, Tai, Yanhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Bedside to Bench Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301797/
https://www.ncbi.nlm.nih.gov/pubmed/30273505
http://dx.doi.org/10.1080/15384047.2018.1480282

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301797/
https://www.ncbi.nlm.nih.gov/pubmed/30273505
http://dx.doi.org/10.1080/15384047.2018.1480282

Ejemplares similares